Building a Diversified Healthcare Platform as Exosome Science, Telehealth, Diagnostics & Strategic Acquisitions Converge: NexTel Medical (OTCID: MAJI)
Sep 16, 2026
With a potential Q4 commercial launch, expanding diagnostic opportunities, a major telehealth platform, veterinary oncology initiatives and a proposed Xycota acquisition, NexTel is positioning $MAJI around multiple potential growth catalysts
SAINT PETERSBURG, Fla. - Sept. 16, 2026 - PRLog -- NexTel Medical Corp. (Stock Symbol: MAJI) is rapidly evolving into a much broader healthcare and biotechnology story than the company investors may have been following earlier this year. Formerly known as Exousia Pro, NexTel has spent 2026 assembling what management describes as an integrated healthcare ecosystem combining proprietary exosome technology, diagnostics, telehealth, pharmaceutical access, wellness products and strategic distribution infrastructure.
The company's most recent developments suggest that the investment story is increasingly centered on commercialization and platform expansion, rather than relying on a single biotechnology program.
Perhaps most importantly, NexTel now has several potential catalysts developing simultaneously.
A Rapidly Expanding NexTel Healthcare Ecosystem
At the heart of the strategy is NexTel's proprietary Maxasome™ technology and its focus on exosome-based delivery systems. The company has been working toward commercializing exosome products while simultaneously developing diagnostic applications, including its proprietary NANOG DNA cancer-screening technology.
In June, NexTel outlined a strategy designed to combine its biotechnology pipeline with revenue-generating healthcare operations. The company said its JumpstartRx and NueVistraMed operations were generating approximately $135,000–$140,000 in monthly revenue, while the broader platform included a network of more than 1,850 online and brick-and-mortar clinics.
That combination could be particularly interesting to investors because it creates the possibility of pairing longer-term biotechnology upside with operating healthcare assets.
Island 40 Acquisition Could Significantly Broaden the Platform
One of the most consequential developments arrived in July when NexTel amended its previously announced transaction to acquire Island 40 Group and its full subsidiary platform, rather than acquiring only individual healthcare businesses.
The proposed transaction carries total consideration of approximately $12.75 million, consisting of $3.5 million in cash and $9.25 million in preferred stock. Island 40's ecosystem includes JumpstartRx, NuevistraMed and additional platforms serving healthcare, wellness, institutional, sports, motorsports and consumer markets.
According to NexTel, Island 40 and its affiliated channels currently reach more than 300,000 patients per month.
For MAJI shareholders, the significance is the potential creation of a much larger distribution engine capable of helping NexTel introduce future products to consumers, healthcare providers, employers and institutional partners.
The transaction remains subject to customary closing conditions, financial review, documentation and due diligence, so investors should view the acquisition as a proposed strategic catalyst rather than a completed transaction.
Xycota: A Potentially Transformative Biotechnology Addition
Then came perhaps NexTel's most intriguing scientific development of the summer.
On August 5, the company announced a definitive Letter of Intent to acquire 100% of Xycota Biosciences, LLC, a preclinical biotechnology company developing exosome-delivered therapeutics designed to target damaged neural networks.
Xycota's lead program, XYCO-01, is being developed around the BDNF-TrkB neuroplasticity pathway, initially targeting Frontotemporal Dementia (FTD), with potential expansion into ALS, mild traumatic brain injury and other neurodegenerative diseases.
If completed, the acquisition could give NexTel exposure to a completely new therapeutic category while remaining closely aligned with its broader exosome strategy.
For investors, the important point is not that these programs are already commercial—it is that NexTel is attempting to build a multi-platform biotechnology company with multiple shots on goal.
Veterinary Oncology Opens Another Potential Market
NexTel $MAJI has also begun looking beyond human healthcare.
In July, the company announced plans to roll out an early-stage cancer screening platform for companion animals using its diagnostic technology. The company intends to process blood samples centrally and work with veterinary oncologists to screen for multiple cancer profiles. NexTel cited a North American pet oncology opportunity exceeding $1 billion.
The veterinary initiative could ultimately provide another recurring diagnostic revenue opportunity while potentially expanding the addressable market for NexTel's technology.
The company's planned Maxasome PLUS formulation for household pets adds another dimension to this strategy. In August, NexTel said it anticipated introducing the veterinary formulation as its third commercial product later this year.
Scientific Validation Remains a Major Watch Point
NexTel's relationship with Pennsylvania State University is another important component of the story.
The company announced a first-of-its-kind exosome characterization study using advanced mass spectrometry to identify bioactive compounds within its proprietary mushroom-derived exosomes. The work is intended to help guide new intellectual property, formulations and product development.
Importantly, the company's latest SEC disclosure now states that the Penn State study is expected to be completed in Q1 2027, rather than the originally anticipated 2026 timeframe.
That delay is worth watching, but successful completion could become an important scientific and intellectual-property catalyst.
Baylor, International Partnerships and New Product Opportunities
NexTel also clarified in August that it and Xycota were finalizing a Material Transfer Agreement involving Baylor University for research examining the anti-aging properties of Maxasome PLUS. The company said product shipments for clinical testing were expected to follow execution of the agreement.
At the same time, NexTel disclosed that its equity ownership in a Japanese partnership had increased from 70% to 75%, with an additional 11.277 million LMMY shares expected to be issued to NexTel under the renegotiated arrangement.
These developments reinforce the increasingly international and diversified nature of the company's strategy.
The Next Major Catalyst: Commercialization
Perhaps the biggest near-term question for MAJI is whether NexTel can translate its technology and acquisitions into meaningful commercial activity.
The company previously announced that its initial exosome products had entered final stability testing after samples tested negative for several key contaminants. NexTel has targeted a Q4 2026 commercial launch and has discussed a potential OTCQB uplisting target for Q1 2027.
The September regulatory filings add another important piece to the picture. On September 3, the SEC qualified NexTel's amended Regulation A offering. The latest offering circular provides for up to 60 million company shares, with remaining company and selling-shareholder shares priced at $0.003 per share under the amended terms.
That financing structure provides potential capital for development, acquisitions, laboratory equipment, marketing and working capital—but investors should also carefully consider dilution and the company's stated risk factors.
What Investors Should Be Watching Now
The MAJI story heading into the final months of 2026 is increasingly defined by execution.
Key potential catalysts include:
The Bigger Picture for MAJI
Rather than pursuing only one technology, NexTel is attempting to assemble an interconnected healthcare platform spanning exosome therapeutics, diagnostics, telehealth, pharmaceuticals, wellness, veterinary medicine and neuro-restoration.
If management can successfully execute on its commercialization plans, close its strategic acquisitions and generate meaningful recurring revenue while advancing its scientific pipeline, NexTel could look substantially different by the end of 2026 than it did at the beginning of the year.
For more information on MAJI visit: www.nextelmedical.com
Media Contact
Company Name: NexTel Medical Corp. (Stock Symbol: MAJI)
Contact Person: Matthew Dwyer, President and CEO
Email: [email protected] or [email protected]
Phone: +1 509-605-6533
Country: United States
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
Photos: (Click photo to enlarge)
Source: CorporateAds
Read Full Story - Building a Diversified Healthcare Platform as Exosome Science, Telehealth, Diagnostics & Strategic Acquisitions Converge: NexTel Medical (OTCID: MAJI) | More news from this source
Press release distribution by PRLog
SAINT PETERSBURG, Fla. - Sept. 16, 2026 - PRLog -- NexTel Medical Corp. (Stock Symbol: MAJI) is rapidly evolving into a much broader healthcare and biotechnology story than the company investors may have been following earlier this year. Formerly known as Exousia Pro, NexTel has spent 2026 assembling what management describes as an integrated healthcare ecosystem combining proprietary exosome technology, diagnostics, telehealth, pharmaceutical access, wellness products and strategic distribution infrastructure.
The company's most recent developments suggest that the investment story is increasingly centered on commercialization and platform expansion, rather than relying on a single biotechnology program.
Perhaps most importantly, NexTel now has several potential catalysts developing simultaneously.
A Rapidly Expanding NexTel Healthcare Ecosystem
At the heart of the strategy is NexTel's proprietary Maxasome™ technology and its focus on exosome-based delivery systems. The company has been working toward commercializing exosome products while simultaneously developing diagnostic applications, including its proprietary NANOG DNA cancer-screening technology.
In June, NexTel outlined a strategy designed to combine its biotechnology pipeline with revenue-generating healthcare operations. The company said its JumpstartRx and NueVistraMed operations were generating approximately $135,000–$140,000 in monthly revenue, while the broader platform included a network of more than 1,850 online and brick-and-mortar clinics.
That combination could be particularly interesting to investors because it creates the possibility of pairing longer-term biotechnology upside with operating healthcare assets.
Island 40 Acquisition Could Significantly Broaden the Platform
One of the most consequential developments arrived in July when NexTel amended its previously announced transaction to acquire Island 40 Group and its full subsidiary platform, rather than acquiring only individual healthcare businesses.
The proposed transaction carries total consideration of approximately $12.75 million, consisting of $3.5 million in cash and $9.25 million in preferred stock. Island 40's ecosystem includes JumpstartRx, NuevistraMed and additional platforms serving healthcare, wellness, institutional, sports, motorsports and consumer markets.
According to NexTel, Island 40 and its affiliated channels currently reach more than 300,000 patients per month.
For MAJI shareholders, the significance is the potential creation of a much larger distribution engine capable of helping NexTel introduce future products to consumers, healthcare providers, employers and institutional partners.
The transaction remains subject to customary closing conditions, financial review, documentation and due diligence, so investors should view the acquisition as a proposed strategic catalyst rather than a completed transaction.
Xycota: A Potentially Transformative Biotechnology Addition
Then came perhaps NexTel's most intriguing scientific development of the summer.
On August 5, the company announced a definitive Letter of Intent to acquire 100% of Xycota Biosciences, LLC, a preclinical biotechnology company developing exosome-delivered therapeutics designed to target damaged neural networks.
Xycota's lead program, XYCO-01, is being developed around the BDNF-TrkB neuroplasticity pathway, initially targeting Frontotemporal Dementia (FTD), with potential expansion into ALS, mild traumatic brain injury and other neurodegenerative diseases.
If completed, the acquisition could give NexTel exposure to a completely new therapeutic category while remaining closely aligned with its broader exosome strategy.
For investors, the important point is not that these programs are already commercial—it is that NexTel is attempting to build a multi-platform biotechnology company with multiple shots on goal.
Veterinary Oncology Opens Another Potential Market
NexTel $MAJI has also begun looking beyond human healthcare.
In July, the company announced plans to roll out an early-stage cancer screening platform for companion animals using its diagnostic technology. The company intends to process blood samples centrally and work with veterinary oncologists to screen for multiple cancer profiles. NexTel cited a North American pet oncology opportunity exceeding $1 billion.
The veterinary initiative could ultimately provide another recurring diagnostic revenue opportunity while potentially expanding the addressable market for NexTel's technology.
The company's planned Maxasome PLUS formulation for household pets adds another dimension to this strategy. In August, NexTel said it anticipated introducing the veterinary formulation as its third commercial product later this year.
Scientific Validation Remains a Major Watch Point
NexTel's relationship with Pennsylvania State University is another important component of the story.
The company announced a first-of-its-kind exosome characterization study using advanced mass spectrometry to identify bioactive compounds within its proprietary mushroom-derived exosomes. The work is intended to help guide new intellectual property, formulations and product development.
Importantly, the company's latest SEC disclosure now states that the Penn State study is expected to be completed in Q1 2027, rather than the originally anticipated 2026 timeframe.
That delay is worth watching, but successful completion could become an important scientific and intellectual-property catalyst.
Baylor, International Partnerships and New Product Opportunities
NexTel also clarified in August that it and Xycota were finalizing a Material Transfer Agreement involving Baylor University for research examining the anti-aging properties of Maxasome PLUS. The company said product shipments for clinical testing were expected to follow execution of the agreement.
At the same time, NexTel disclosed that its equity ownership in a Japanese partnership had increased from 70% to 75%, with an additional 11.277 million LMMY shares expected to be issued to NexTel under the renegotiated arrangement.
These developments reinforce the increasingly international and diversified nature of the company's strategy.
The Next Major Catalyst: Commercialization
Perhaps the biggest near-term question for MAJI is whether NexTel can translate its technology and acquisitions into meaningful commercial activity.
The company previously announced that its initial exosome products had entered final stability testing after samples tested negative for several key contaminants. NexTel has targeted a Q4 2026 commercial launch and has discussed a potential OTCQB uplisting target for Q1 2027.
The September regulatory filings add another important piece to the picture. On September 3, the SEC qualified NexTel's amended Regulation A offering. The latest offering circular provides for up to 60 million company shares, with remaining company and selling-shareholder shares priced at $0.003 per share under the amended terms.
That financing structure provides potential capital for development, acquisitions, laboratory equipment, marketing and working capital—but investors should also carefully consider dilution and the company's stated risk factors.
What Investors Should Be Watching Now
The MAJI story heading into the final months of 2026 is increasingly defined by execution.
Key potential catalysts include:
- Q4 2026 commercial launch of NexTel's exosome products.
- Progress toward closing the Island 40 Group acquisition.
- Development of the proposed Xycota Biosciences acquisition.
- Baylor research and additional Maxasome PLUS testing.
- Veterinary oncology and pet-product commercialization.
- Advancement of the NANOG cancer-screening platform.
- Completion of the Penn State exosome characterization study, now expected in Q1 2027.
- Potential progress toward an OTCQB uplisting.
The Bigger Picture for MAJI
Rather than pursuing only one technology, NexTel is attempting to assemble an interconnected healthcare platform spanning exosome therapeutics, diagnostics, telehealth, pharmaceuticals, wellness, veterinary medicine and neuro-restoration.
If management can successfully execute on its commercialization plans, close its strategic acquisitions and generate meaningful recurring revenue while advancing its scientific pipeline, NexTel could look substantially different by the end of 2026 than it did at the beginning of the year.
For more information on MAJI visit: www.nextelmedical.com
Media Contact
Company Name: NexTel Medical Corp. (Stock Symbol: MAJI)
Contact Person: Matthew Dwyer, President and CEO
Email: [email protected] or [email protected]
Phone: +1 509-605-6533
Country: United States
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
Photos: (Click photo to enlarge)
Source: CorporateAds
Read Full Story - Building a Diversified Healthcare Platform as Exosome Science, Telehealth, Diagnostics & Strategic Acquisitions Converge: NexTel Medical (OTCID: MAJI) | More news from this source
Press release distribution by PRLog
More News
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.